112 related articles for article (PubMed ID: 6500745)
1. Immune rejection mechanisms in murine leukemia. I. Timing of tumor cell rejection process relative to the development of humoral and cell-mediated cytotoxic immune responses.
Ciavarra RP; Terres G
Int J Cancer; 1984 Nov; 34(5):681-8. PubMed ID: 6500745
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous development of humoral and cellular tumor-specific immunity against L1210 mouse leukemia.
Kawashima K; Isobe K; Nagase F; Yokochi T; Nagura E; Hasegawa Y; Morishita H; Yamada K; Nakashima I
Leuk Res; 1985; 9(7):935-9. PubMed ID: 4021540
[TBL] [Abstract][Full Text] [Related]
3. Common leukemia-associated antigen of DBA/2 mouse leukemia detected by tumor rejection and complement-dependent cytotoxicity assays.
Kawashima K; Takeyama H; Takahashi T; Kato Y; Watanabe E; Suzuki H; Minam S; Isobe K; Yamada K; Ito Y
Gan; 1979 Dec; 70(6):769-76. PubMed ID: 94022
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic tumor enhancement by levamisole, a new immunostimulatory compound: studies on cell-mediated immunity and humoral antibody response.
Mantovani A; Spreafico F
Eur J Cancer (1965); 1975 Aug; 11(8):537-44. PubMed ID: 1222761
[No Abstract] [Full Text] [Related]
5. Development of host-dependent high-grade tumor-specific immunity through a novel mechanism triggered by the Lyt-2+ tumor-specific T cell clone (K7L) that induces temporal growth of L1210 leukemia-K7L-variant.
Nagase F; Ueda K; Kawashima K; Jamshedur Rahman SM; Isobe K; Yoshida T; Hasegawa Y; Ando K; Iwamoto T; Nagura E
J Immunol; 1987 Apr; 138(7):2359-65. PubMed ID: 2951438
[TBL] [Abstract][Full Text] [Related]
6. Mode of alloantibody-mediated blockade of allo-sensitization for tumor allograft rejection.
Lai H; Hasegawa Y; Mizoguchi K; Yoshida T; Isobe K; Shimokata K; Kawashima K; Nakashima I
Immunobiology; 1989 Mar; 179(1):33-43. PubMed ID: 2786494
[TBL] [Abstract][Full Text] [Related]
7. OK-432-mediated augmentation of antitumor immunity and generation of cytotoxic T lymphocytes.
Ujiie T
Jpn J Exp Med; 1987 Apr; 57(2):103-15. PubMed ID: 3499533
[TBL] [Abstract][Full Text] [Related]
8. Humoral antibody and cell-mediated cytotoxicity responses of mice to rat skin xenografts.
Hines DL; Cowall C; Lang RW
Transplantation; 1976 May; 21(5):375-80. PubMed ID: 775701
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells.
Langer A; Valdivia LA; Murase N; Woo J; Celli S; Fung JJ; Starzl TE; Demetris AJ
Am J Pathol; 1993 Jul; 143(1):85-98. PubMed ID: 7686346
[TBL] [Abstract][Full Text] [Related]
10. Specific recognition and rejection of the H-2-deficient cell line LR.4 by C57BL/6J mice.
Verastegui E; del Rio R; Ortega V; Alfaro G
Eur J Immunogenet; 1997 Apr; 24(2):93-103. PubMed ID: 9104580
[TBL] [Abstract][Full Text] [Related]
11. Echinococcus multilocularis: parasite-specific humoral and cellular immune response subsets in mouse strains susceptible (AKR, C57B1/6J) or 'resistant' (C57B1/10) to secondary alveolar echinococcosis.
Gottstein B; Wunderlin E; Tanner I
Clin Exp Immunol; 1994 May; 96(2):245-52. PubMed ID: 7910534
[TBL] [Abstract][Full Text] [Related]
12. Effect of levamisole on cytotoxic T-cell-mediated immune resistance to L1210 murine leukemia in hyperimmune mice.
Gomi K; Morimoto M; Kataoka T
Cancer Immunol Immunother; 1984; 17(3):195-9. PubMed ID: 6332672
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunotoxicity of 2,2'-dichlorodiethyl sulfide and cyclophosphamide: evaluation of L1210 tumor cell resistance, cell-mediated immunity, and humoral immunity.
Blank JA; Joiner RL; Houchens DP; Dill GS; Hobson DW
Int J Immunopharmacol; 1991; 13(2-3):251-7. PubMed ID: 2071298
[TBL] [Abstract][Full Text] [Related]
14. The effects of passive immunization with tumor-specific antiserum on the active immune response of mice to sublines of leukemia L1210.
Carlson GA; Terres G
J Immunol; 1978 Nov; 121(5):1752-9. PubMed ID: 712064
[TBL] [Abstract][Full Text] [Related]
15. Antibody-induced killing in vivo of L1210/MTX-R cells quantitated in passively immunized mice with 131I-iododeoxyuridine-labeled cells and whole-body measurement of retained radioactivity.
Carlson GA; Terres G
J Immunol; 1976 Sep; 117(3):822-9. PubMed ID: 956654
[TBL] [Abstract][Full Text] [Related]
16. Immune mechanisms in organ allograft rejection. III. Cellular and humoral immunity in rejection of organ allografts transplanted across MHC subregion disparity RT1.B (RT1.D).
Lowry RP; Gurley KE
Transplantation; 1983 Oct; 36(4):405-11. PubMed ID: 6353708
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
18. Cellular and humoral immunity to leukemia cells in BCG-induced growth control of a murine leukemia.
Olsson L; Florentin I; Kiger N; Mathé G
J Natl Cancer Inst; 1977 Oct; 59(4):1297-306. PubMed ID: 904001
[TBL] [Abstract][Full Text] [Related]
19. Hexachlorobenzene-induced stimulation of the humoral immune response in rats.
Vos JG; van Logten MJ; Kreeftenberg JG; Kruizinga W
Ann N Y Acad Sci; 1979 May; 320():535-50. PubMed ID: 378061
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and amplifier cell production by tumor vaccines enhanced by concanavalin A.
Kataoka T; Oh-Hashi F; Sakurai Y
Gan; 1982 Apr; 73(2):193-205. PubMed ID: 6811360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
